Management

Sten R. Sörensen has been the CEO of Cereno Scientific since 2015 and has extensive experience from the pharma, biotech, and finance industries. Prior to Cereno Scientific, he held senior positions in major pharma including Head of International Marketing Operations for the 10 BSEK pharma portfolio at Monsanto and Global Marketing Director for the 4 BSEK portfolio of Secondary Prevention Products, Cardiovasculars at AstraZeneca. At Monsanto and AstraZeneca, he initiated two groundbreaking preventive survival studies in heart failure, RALES and MERIT-HF, both establishing a paradigm shift for mineralocorticoid receptor (MR) antagonism and beta-blocker drug therapies in heart failure, significantly improving quality of life and life expectancy. He was also a Board member of Cereno Scientific between 2014-2016. Sten holds a bachelor’s degree in chemistry from Lund University. He is the Chairman of SARomics Biostructure and board member of SynAct Pharma.

Considered dependent of the company and its management, but independent of major shareholders.

Shareholding: 1,995,179 Class B shares and 5,000,000 warrants

Born 1965. Dr. Rahul Agrawal is an experienced senior executive leader with a diverse background spanning Big Pharma and biotech. His expertise encompasses the entire value chain including R&D, Medical Affairs, commercial and strategy experience across various therapeutic areas such as cardiovascular, renal, respiratory, and rare/orphan drugs and he has launched seven drugs globally. Previous roles include CMO at Cardior, VP and Global Medicines Leader at AstraZeneca, and Global Director of Medical Affairs and Clinical Development at Bayer HealthCare. Dr. Agrawal has an MD degree from the Free University of Berlin, Germany and Cornell University, New York, USA, and is board-certified in cardiology, internal medicine, and emergency medicine. Additionally, he holds an MBA from Buckinghamshire New University, UK.

Shareholding: 2,000,000 warrants

Born 1953. Björn Dahlöf has over 35 years of clinical experience added to his extensive experience in cardiovas­cular research, pharmacology, drug development, and clinical trials (all phases) and has lectured in these areas internationally. Adviser to small and large pharmaceutical companies regarding drug development in all phases from preclinical development to larger lifecycle management stud­ies after registration. Björn Dahlöf has initiated and led several major national and multinational mortality and morbidity studies that have had significance for guidelines in cardio­vascular prevention and authored over 400 scientific publications. Dr. Björn Dahlöf is a Medical Doctor from the University of Gothenburg, internal medicine physician and associate professor at Sahlgrenska University Hospital, University of Gothenburg.

Shareholding: 123 920 A shares, 1,439,076 B shares, 333,333 Qualified Personnel Warrants and 2,500,000 Warrants Series 2023/2026:1

Born 1966. Eva Jagenheim has a broad experience of various roles within finance. Previous experience includes working as an accountant at PWC, consultant at the accounting firm Arthur Andersen, and at companies of varying sizes across several dif- ferent industries. She most recently worked as CFO at RLS Global, a medtech company listed on Nasdaq First North Growth Market. Eva Jagnheim has a M.Sc. in Business and Economics from Växjö University and an MBA from Gothenburg Business School.

Shareholding: 275,000 Class B shares and 1,000,000 warrants of series 2023/2026

Born 1961. Nicholas Oakes has more than 20 years of experience working in the pharmaceutical industry with both efficacy and safety-related aspects of preclinical research to discover and develop new effective and safe medicines in metabolic, cardiovascular, and renal disease areas. Nicholas Oakes holds a Ph.D. in cardiovascular and metabolic research from the University of New South Wales, Sydney, Australia.

Shareholding: 250,000 warrants of series 2023/2026 and 333,333 warrants of series KPO

Born 1988. Skilled professional in communications, investor relations and integrated marketing within life sciences and healthcare. Specialized in public biotech companies headquartered in the Nordics. Broad experience in milestone communications at various points of the business and product life cycle to disease awareness and patient adherence to brand building to crisis and issues management on global, regional and local markets. Previous experience in global healthcare PR for AstraZeneca, Merck KGaA and Bayer. Tove Bergenholt holds a M.Sc. in Digital Business Management from Manchester Metropolitan University, UK. Dual B.Sc. in Business Administration with specialization in Business Development and Accounting from the University of Borås. Tove has worked with the company in a consultancy capacity since 2020.

Shareholding: -